Xiaoyang Xu - Sino Biopharmaceutica CEO
| SBMFF Stock | USD 0.31 0.04 11.43% |
CEO
Mr. Xu Xiaoyang is the Chief Executive Officer Executive Director of Sino Biopharmaceutical Ltd. He joined the Group in September 2007. He is the Chief Executive Officer of the Company and the chairman of Shanghai Tongyong. He also served as President senior engineer and practicing pharmacist of the Group. He is responsible for affairs with government authorities management of various subsidiaries and certain investment projects of the Group. He obtained a Bachelor Degree in Industrial Science from Chinese Medicine Department of the Business Faculty of Harbin University of Commerce . Before joining the Group he had worked as chief engineer and general manager in Tianjin Darentang Pharmaceutical Factory. In 1992 Mr. Xu was selected by the SinoJapan Association for International Exchange of Talents for the Japan Association for Overseas Technical Scholarship program and studied research and development and management for one year with Matsuura Yakugyo Japan and obtained an education proof. He has also studied a Master Degree of Business Administration in Tianjin University of Finance and Economics during 1997 and 1998. In 1999 he also studied Business Administration in Technische Fachhochschule Berlin. since 2009.
| Age | 51 |
| Tenure | 15 years |
| Phone | 852 2802 9886 |
| Web | https://www.sinobiopharm.com |
Sino Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0451 % which means that it generated a profit of $0.0451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2908 %, meaning that it generated $0.2908 on every $100 dollars invested by stockholders. Sino Biopharmaceutica's management efficiency ratios could be used to measure how well Sino Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Gilles Gagnon | Ceapro Inc | 62 | |
| Brian Pedlar | Covalon Technologies | N/A | |
Management Performance
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 |
Sino Biopharmaceutical Leadership Team
Elected by the shareholders, the Sino Biopharmaceutica's board of directors comprises two types of representatives: Sino Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sino. The board's role is to monitor Sino Biopharmaceutica's management team and ensure that shareholders' interests are well served. Sino Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sino Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiquan Zhang, Chief Engineer of JCTT | ||
| Cheung Cheng, Executive Director and Member of Executive Board Committee | ||
| Wei Ye, Assistant President Deputy General Manager - R&D Department | ||
| Shanchun Wang, General Engineer of JCTT | ||
| Mingqin Li, Vice President Director and Deputy General Manager of CTGC and the director of Beijing Tide | ||
| Chau Yu, Assistant Vice President Financial Controller | ||
| Jinming Li, Deputy General Manager of LYG Tianqing | ||
| Fai Chia, Assistant to the Chairman, Personnel Manager | ||
| Hsin Tse, VP, General Manager of Audit Department, Executive Director and Member of Executive Board Committee | ||
| Zhaoshu Gu, Senior Engineer | ||
| Hsuan Tse, General Manager - Information Management Department | ||
| Xiaoyang Xu, CEO, Executive Director and Member of Executive Board Committee | ||
| Zhengfei Lu, Independent Non-Executive Director | ||
| Ping Tse, Founder and President Compliance Officer, Executive Director, Member of Executive Board Committee and Member of Nomination Committee | ||
| Xiangjian Wang, Vice President of CTT | ||
| Xiaoguang Shen, General Manager - Investment Management Department | ||
| Kong Tai, Managing Director Of Beijing Tide | ||
| Xinglong Zhuang, Assistant to the President and Secretary of the board of CTT | ||
| Sau Leung, Vice President Company Secretary | ||
| Yangsheng Chen, Deputy General Manager - of R&D of Qingdao CT | ||
| Y Tse, Executive Chairman of the Board | ||
| Jie Zhang, Vice President of CTT | ||
| Wenyu Xia, General Manager and Director of Jiangsu Fenghai | ||
| Minggang Wang, Vice Chairman of the Board and the General Manager of Qingdao Haier | ||
| Wun Tse, Assistant to the Chairman | ||
| Dakui Li, Independent Non-Executive Director | ||
| Yong Zhu, President of Jiangsu Qingjiang | ||
| Zhaocheng Tang, Vice President of JCTT | ||
| Ling Zhang, Deputy General Manager and the Secreatary to the board of directors of NJCTT | ||
| Hong Lu, Independent Non-Executive Director | ||
| Chun Li, Vice President of JCTT | ||
| Oi Chan, Company Secretary | ||
| Lu Zhang, Independent Non-Executive Director | ||
| Eric Tse, CEO Director | ||
| Zong Liu, Senior Engineer | ||
| Ren Li, General Manager - of Qingdao CT | ||
| Ziping Xu, Senior Engineer | ||
| Junping Wang, General Manager of Shanghai Tongyong | ||
| Fangzhui Hu, Vice President of CT Tianqing | ||
| Haihua Liu, General Manager - of Jiangsu CT Fenghai | ||
| Hong Wang, Deputy General Manager of LYG Tianqing | ||
| Zhenqian Zhang, Deputy General Manager and Engineer of NJCTT | ||
| Sheng Chen, Financial Controller and Deputy General Director | ||
| Hui Cheng, Deputy Financial Controller | ||
| Zhoushan Tian, Vice President of JCTT and General Manager of NJCTT | ||
| Qiang Yao, General Manager of Sales Department of CT Tianqing | ||
| Yangqing Zhang, Deputy General Manager of finance department of NJCTT | ||
| Kuanqi Wang, Deputy General Manager of NJCTT | ||
| Hongqi Wang, Deputy General Manager of NJCTT | ||
| Fajun Cai, General Manager of the sales Department of CT Tianqing | ||
| Wenjun Shi, General Manager of the sales Department of CT Tianqing |
Sino Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sino Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 18.81 B | |||
| Shares Owned By Insiders | 47.86 % | |||
| Shares Owned By Institutions | 14.86 % | |||
| Price To Earning | 24.17 X | |||
| Price To Book | 2.51 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sino Biopharmaceutical Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Sino Biopharmaceutical information on this page should be used as a complementary analysis to other Sino Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Sino Pink Sheet analysis
When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |